What happens to stocks if AI loses momentum?
NEW YORK - TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company with a market capitalization of $5.4 billion and impressive revenue growth of 41% in the last twelve months, today shared findings from two recent publications on multiple sclerosis (MS) treatments, highlighting experiences of patients switching to its drug BRIUMVI® (ublituximab-xiiy) from other anti-CD20 therapies. The company’s Executive Chairman and CEO, Michael S. Weiss, expressed optimism about the potential of BRIUMVI® to improve outcomes for MS patients seeking alternative treatments. According to InvestingPro analysis, the company maintains an exceptional gross profit margin of 88.3%, suggesting strong pricing power for its therapeutic solutions.
The first publication, a case series from Frontiers in Immunology, detailed the outcomes of seven MS patients who switched to BRIUMVI® due to concerns with the efficacy or tolerability of their prior anti-CD20 monoclonal antibody therapy. The cases showed clinical and radiological improvements after the switch. The second article, published in CNS DRUGS, reviewed the evolution of anti-CD20 treatments for MS, discussing the scientific rationale for switching within the same class of drugs. The market has responded positively to these developments, with TG Therapeutics’ stock delivering an impressive 157% return over the past year.
TG Therapeutics emphasized the significance of these findings in the context of its ongoing ULTIMATE I & II Phase 3 trials, which are evaluating BRIUMVI® in a head-to-head comparison with teriflunomide, an oral MS drug. These international trials aim to further substantiate the anecdotal evidence from the case reports.
BRIUMVI® is an intravenously administered monoclonal antibody targeting CD20-expressing B-cells, a key component in the management of autoimmune disorders like MS. The drug’s design allows for efficient B-cell depletion at lower doses due to a process called glycoengineering, which removes certain sugar molecules from the antibody.
The press release also outlined safety information for BRIUMVI®, noting contraindications such as active Hepatitis B Virus infection and history of life-threatening infusion reactions to the drug. It highlighted potential side effects including infusion reactions and infections, with a particular warning about the risk of Hepatitis B Virus reactivation.
TG Therapeutics is a biopharmaceutical company focused on novel treatments for B-cell diseases. BRIUMVI® is FDA-approved for adult patients with various forms of relapsing MS. The company offers support programs for U.S. patients and continues to engage in research and development to address the needs of the MS community. Financial metrics from InvestingPro indicate strong operational efficiency, with analysts expecting continued net income growth this year. The platform offers 17 additional ProTips and detailed financial analysis for investors seeking deeper insights into TG Therapeutics’ market position and growth potential.
The information in this article is based on a press release statement from TG Therapeutics, Inc.
In other recent news, TG Therapeutics reported strong financial results for the fourth quarter of 2024, with earnings per share (EPS) of $0.15, surpassing the analyst estimate of $0.08. The company’s revenue for the quarter reached $108.2 million, exceeding the consensus estimate of $97.66 million, and marking a significant year-over-year growth. TG Therapeutics’ full-year revenue totaled $329 million, driven by $310 million in net sales of Briumvi in the U.S. H.C. Wainwright maintained a Buy rating for TG Therapeutics, setting a $55 target, while Cantor Fitzgerald reiterated an Overweight rating, indicating confidence in the company’s prospects.
Roche announced that its Phase III MUSETTE trial of a higher dose of Ocrevus for relapsing multiple sclerosis did not meet its primary endpoint. The trial aimed to assess if a higher dose could offer additional benefits, but results showed that the 600 mg dose remains optimal. Despite the setback, the higher dose was well tolerated with no new safety signals, supporting the continued use of the 600 mg dose. Roche also launched Ocrevus Zunovo™, enhancing treatment options for multiple sclerosis patients, and continues to explore other formulations and targets in its pipeline.
These recent developments reflect the ongoing dynamics in the biopharmaceutical sector, with TG Therapeutics showing strong financial performance and Roche focusing on optimizing its multiple sclerosis treatments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.